1-(Tert-Butoxycarbonyl)-3-Methylpyrrolidine-3-Carboxylic Acid

Incorporation of 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid into solid-phase peptide synthesis sequences is governed by the steric demand of the fully substituted Cα center, which distinguishes its coupling behaviour from that of proline or 3-substituted proline derivatives. When the scaffold is deployed as an N-terminal building block on Rink amide or Wang resin with a loading of 0.4–0.8 mmol/g, the activation–coupling protocol must be adjusted to compensate for the reduced nucleophilicity of the secondary amine liberated after Boc removal. Production-scale protocols, reproduced across multiple CDMO batch records, converge on a charge of 3.0–4.5 molar equivalents of 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid relative to the free amine on-resin, pre-activated with 3.5–4.2 equivalents of HBTU or HATU and 8–10 equivalents of N,N-diisopropylethylamine in anhydrous DMF for 45–90 min at 25±2 °C. In situ neutralisation following 40% TFA in DCM (v/v) deprotection is performed immediately upstream of the coupling module to minimise diketopiperazine formation, a documented failure mode when a secondary amine immediately follows a glycine or sarcosine residue. The terminal product pool comprises peptidomimetic lead candidates directed against Class B GPCR targets, where the quaternary pyrrolidine residue imposes a trans-amide bond geometry that enhances proteolytic stability in the gut lumen, with finished peptide purity exceeding 98.5% by UPLC-PDA when the crude is processed on a C18 semi-preparative column with a water–acetonitrile gradient containing 0.1% TFA; compliance with ICH Q7A (Section 7.3) for cleaning validation and residual TFA specification below 0.5% by ion chromatography is mandatory when the peptide is transitioned to GLP toxicology batches.

Preventing Base-Catalyzed Epimerization of the Quaternary Carbon During Peptide Fragment Condensation

Solution-phase coupling of 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid with chiral amino esters or amino alcohols in the presence of tertiary amine bases introduces a measurable risk of racemisation at the C3 stereocenter, a phenomenon that parallels the behaviour of α,α-disubstituted amino acids where enolate formation is promoted by the inductive effect of the carboxamide carbonyl. The epimerisation half-life in a DMF–pyridine (4:1 v/v) mixture with 1.05 equivalents of DIPEA shortens to below 12 minutes when the internal temperature exceeds 5 °C, as monitored by chiral SFC under conditions specified in USP General Chapter <621>. To preserve enantiomeric integrity during kilogram-lab-scale campaigns, process chemists substitute a low-temperature mixed anhydride protocol: activation with isobutyl chloroformate (1.02 eq) and N-methylmorpholine (1.15 eq) in THF at −15 to −10 °C, followed by dropwise addition of the amine nucleophile (1.00 eq) dissolved in THF with 5 vol% NMP. The quenched reaction mass is washed with 1 M citric acid and 8% w/w NaHCO₃ to remove unreacted acid and N-methylmorpholine hydrochloride, after which the organic layer is dried over Na₂SO₄ and concentrated below 40 °C under reduced pressure. This sequence consistently retains the desired ≥ 99.0% ee as determined by a Chiralpak IA-3 column with a hexane–ethanol–TFA mobile phase. The target downstream products are modified dipeptide aldehydes that act as transition-state analogue inhibitors of cathepsin cysteine proteases, where the methylpyrrolidine ring occupies the S1′ pocket; the diastereomeric impurity originating from racemisation reduces target binding by a factor of 10² to 10³ in biochemical FRET-based inhibition assays, a direct engineering constraint that drives the investment in cryogenic reactor trains with jacket recirculation down to −25 °C.

Boc-Protecting Group Survival in HFIP-Based Peptide Fragment Couplings and Its Effect on Large-Scale Oligomer Assembly

When 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid is introduced into a growing linear sequence destined for on-resin cyclisation or segment condensation, the acid lability of the Boc group must be reconciled with the prolonged exposure to 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) often used to mitigate aggregation of polyproline-like stretches. Kinetic profiling on a 2-methylindole-type resin reveals that the tert-butyloxycarbonyl group undergoes 4.2–5.8% premature cleavage after 3 h in 30% HFIP–DCM (v/v) at 20 °C, compared with 0.3–0.6% for Fmoc cleavage under the same conditions when piperidine is omitted. Manufacturers operating peptide synthesizers with ≥ 100 mmol column diameter respond by limiting HFIP exposure to ≤ 45 minutes per cycle and interposing a 10-column-volume THF wash between the HFIP treatment and the subsequent coupling step. The raw material specification for the acid itself incorporates a residual trifluoroacetic acid limit of ≤ 0.05% w/w (tested per Ph. Eur. 2.5.34 method) because trace TFA carried over from the manufacturing isolation accelerates the premature deblocking to an extent that generates +0.8–1.2% double-incorporation frames in the total ion chromatogram. Terminal finished products branching from this route encompass backbone-stapled peptides and integrin-targeting RGD mimetics, where the methylpyrrolidine residue replaces a valine or isoleucine to induce a type VI β-turn conformation. The drug substance batch is released against a monoisotopic mass accuracy of ≤ 3 ppm on a Q-TOF instrument calibrated per ICH Q2(R2), with residual palladium from any prior C–H activation step controlled below 10 ppm per USP <232>.

In the context of CNS-targeted fragment-to-lead campaigns, 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid is dehydrated and condensed with a set of primary amines to generate a collection of N-Boc-3-methylpyrrolidine-3-carboxamide derivatives that probe the magnesium-dependent kinase hinge region. The acid is dissolved in dichloromethane (0.2 M) and treated with 1.05 equivalents of ethyl chloroformate and 1.1 equivalents of triethylamine at 0 °C for 20 minutes to form the mixed anhydride; aliphatic and heteroaryl amines are then introduced as 0.95 equivalents in dry DCM, and the bath is allowed to warm to 22 °C over 2 h. The crude amides are purified on silica gel 60 columns with a hexane–ethyl acetate gradient, and the Boc group is retained for subsequent chemoproteomic pull-down experiments. No freely available pharmacopoeial monograph covers the raw acid in this high-throughput chemistry setting; the internal release criteria instead invoke ICH Q3C residual solvent limits for dichloromethane (≤ 600 ppm) and pyridine (≤ 200 ppm), and the water content is stringently controlled at ≤ 0.1% w/w by Karl Fischer titration to avert mixed anhydride hydrolysis. The final library compounds, structurally related to the pyrrolidinyl-urea class of selective serotonin reuptake inhibitors, are profiled in radioligand displacement assays at 10 μM initial concentration and further optimised using parallel microscale chemistry before the Boc protection is removed under acidic conditions to deliver the secondary amine pharmacophore.

What Is the Minimum Drying Regimen Before a Kilo-Lab Reductive Amination Using This Pyrrolidine Acid?

Reductive amination of the free amine — generated by quantitative TFA-mediated Boc deprotection — necessitates absolute dryness of the intermediate hydrochloride salt to prevent borohydride-derived hydrogen evolution and imine reduction quenching. When the salt is dried under ≤ 10 mbar at 35 °C for 16 h over phosphorus pentoxide, the residual moisture drops below 0.08%, at which point the reaction proceeds cleanly with 1.8 equivalents of sodium cyanoborohydride in methanol containing 1% acetic acid at 20–25 °C. In one CDMO technology transfer report, a batch dried under rotary evaporation alone (40 °C, 48 mbar) retained 1.2% water, resulting in a 38% yield drop and formation of a des-methyl side product identified by HSQC as the product of competitive alcohol formation from the quaternary carboxylic acid precursor. This failure mode drove the institution of a mandatory 2-stage tray dryer protocol with nitrogen sweeping, directly aligned with ISO 9001:2015 quality planning requirements for process robustness. The reductive amination substrate is typically a cyclopentyl- or bicyclo[1.1.1]pentylamine derivative, and the condensed product, after Boc reprotection, enters the supply chain as a late-stage intermediate for a nucleotide prodrug targeting hepatitis B virus reverse transcriptase. The final active substance is tested against the monographs of the relevant regional pharmacopoeia (USP or Ph. Eur.) for related substances (≤ 0.10% single impurity), and the residual cyanide level is validated below 10 ppm via headspace GC with electron-capture detection per method Ph. Eur. 2.4.29.

Using the Acid as an Internal Standard in Quantitative ¹⁹F NMR of Fluorinated Oligopeptide Process Samples

A less-publicised but operationally critical application occurs not in the synthesis itself but in the QC laboratory where 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid, bearing no fluorine atom, serves as a gravimetric internal reference for quantitative ¹⁹F NMR analysis of fluorinated peptide intermediates. Process samples from a continuous-flow peptide synthesizer are spiked with a precisely weighed amount of the compound (10.0 ± 0.05 mg), dissolved in DMSO-d₆, and the ¹⁹F signal intensity of the fluorinated residue is integrated against the ¹H singlet of the tert-butyl group at 1.38 ppm, which is calibrated to a primary standard of dimethyl sulfone traceable to NIST SRM 942. The method, validated per ICH Q2(R2) guidelines within a linearity range of 0.5–50 mg/mL, eliminates the matrix-dependent relaxation effects that plague external standard quantification in non-deuterated flow-cell setups. The acceptance criterion for the release of peptide active pharmaceutical ingredients produced under FDA 21 CFR Part 210/211 requires that the ¹⁹F content by this method agree with the gravimetric batch composition within ± 1.5%. The operational boundary is strict: proton paramagnetic relaxation agents must not be added to the NMR tube because the pyrrolidine ring’s α-protons relax through a cross-correlation mechanism that would distort the integration baseline when Cr(III) species are present; this incompatibility is recorded in the analytical transfer protocol for any CMO assuming the method.

A less-explored but structurally directed use is the conversion of the acid into a mixed disulfide reagent for site-specific labeling of cysteine residues in biosimilar mAb drug substance. 1-(Tert-Butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid is transformed into its N-hydroxysuccinimide ester using 1.08 equivalents of EDC·HCl and 1.0 equivalent of NHS in dioxane–water, then reacted with cystamine dihydrochloride in the presence of 2.5 equivalents of triethylamine to install a Boc-protected pyrrolidine-acetyl-thioethyl disulfide linker. In a production run of an IgG1κ biosimilar expressed in CHO-K1 cells, the protein solution (20 mg/mL in 50 mM Tris-HCl, 5 mM EDTA, pH 7.5) was treated with 2.5 molar equivalents of the disulfide reagent relative to the engineered unpaired cysteine in the CH2 domain; full conversion was achieved in 45 minutes at 25 °C with no detectable aggregation as measured by SEC-MALS. The critical quality attribute monitored is the residual free thiol content, which is titrated with 5,5′-dithiobis(2-nitrobenzoic acid) and maintained below 0.02 mol/mol protein to satisfy ICH Q6B specifications for chemically conjugated biologics. The terminal product is a cytotoxic drug-conjugate intermediate in which the Boc group is later removed under mildly acidic conditions to unmask a membrane-permeable secondary amine that aids lysosomal escape of the payload.

Direct manufacturing utilisation of 1-(tert-butoxycarbonyl)-3-methylpyrrolidine-3-carboxylic acid for a commercial dipeptidyl peptidase IV inhibitor requires a pre-shipment conditioning that is absent from laboratory-scale work instructions: the material must be micronised through an air-jet mill with a classifier speed set to 10 000 rpm to achieve a median particle size (D50) of 8–15 μm and then re-dried on a vacuum tray dryer at 40±2 °C for 12 hours under a nitrogen stream because the milling operation introduces 0.2–0.4% surface moisture by condensation on the newly created surfaces. When the micronised acid is deployed in a slurry-to-slurry amidation with a hydrochloride salt of an amino pyrrolidine in iso-propyl acetate with 2.0 equivalents of propylphosphonic anhydride (T3P, 50 wt% in EtOAc) and 2.5 equivalents of triethylamine, the heterogeneous reaction exhibits a maximum yield plateau of 92% after 5 hours at 25 °C and is mass-transfer-limited; process engineers responsible for the 2000-L GLMS reactor train have identified that the pseudo-Kolbe-Schmitt kinetic model fails to describe the 0–90% conversion window unless the particle size distribution is integrated into the simulation. The resulting protected amino amide is the direct penultimate precursor to a marketed oral antihyperglycaemic agent, and its release specifications are aligned with ICH M7(R2) for mutagenic impurity control; 2-cyanopyridine, which arises from a minor elimination pathway of the coupling reagent, is controlled below 1.5 μg/g and monitored by LC-MS/MS in multiple reaction monitoring mode on each production batch.